Influence of educational status on compliance and psychological outcomes of injectable contraceptive use among postpartum mothers
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20254147Keywords:
Depot medroxyprogesterone acetate, Postpartum women, Injectable contraceptive, Compliance, Educational status, CES-D scoreAbstract
Background: Injectable depot Medroxyprogesterone acetate (DMPA) is a progestogen-only contraceptive widely used in the postpartum period. Despite its efficacy, there is limited regional data on compliance patterns and psychological impacts associated with its use among postpartum women in Eastern India. The objectives were to assess the clinical and biochemical adverse drug reactions of DMPA, analyze compliance levels in relation to educational status and evaluate psychological outcomes using the CES-D depression scale in postpartum mothers.
Methods: This cross-sectional observational study included 107 postpartum women attending the Antara Clinic under the Department of Community Medicine, Medical College, Kolkata. Inclusion criteria were women aged 18–45 years who received at least one DMPA injection within the past year. Compliance was determined through DMPA card review. Depression was evaluated using the CES-D scale and lipid profiles were analyzed.
Results: The mean age of participants was 27.14±4.28 years. Of the total, 50% had received their first injection, 36% the second, and 15% three or more. ADRs were reported in 91% of participants, predominantly menstrual abnormalities (64%), weight gain (40%), and headache (10%). Amenorrhea was more common among ≥3 injection recipients (43%). Compliance was observed in 56% of participants and was significantly associated with educational status; 83% of those with secondary or higher education showed good compliance (p<0.001; OR=18.5). Discontinuation was most commonly due to irregular spotting (30%). Depression scores (CES-D≥16) were significantly higher in those receiving ≥3 injections (81%) (p=0.001; OR=7.616).
Conclusion: The study highlights a significant association between educational status and compliance with DMPA use. Pre-treatment counselling, especially for women with lower educational levels, is crucial to improving adherence and managing adverse outcomes.
Metrics
References
Government of India. Census 2011: Provisional Population Report. Office of the Registrar General & Census Commissioner, India. 2015. Available at: https://censusindia.gov.in/2011census. Accessed on 28 September 2025.
Shah IH, Åhman E. Unsafe abortion differentials in 2008 by age and developing country region: high burden among young women. Reprod Health Matters. 2012;20(39):169-73. DOI: https://doi.org/10.1016/S0968-8080(12)39598-0
Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A. Contraception and health. Lancet. 2012;380(9837):149-56. DOI: https://doi.org/10.1016/S0140-6736(12)60609-6
Singh S, Darroch JE, Ashford LS, Vlassoff M. Adding it up: The costs and benefits of investing in family planning and maternal and newborn health. Guttmacher Institute. 2009. Available at: https://www.guttmacher.org/sites/default/files/pdfs/pubs/AddingItUp2009.pdf. Accessed on 28 September 2025.
Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med. 1998;43(2):73-83.
Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1-103. DOI: https://doi.org/10.15585/mmwr.rr6503a1
World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO. 2015. Available at: https://www.afro.who.int/sites/ default/files/2017-06/WHO_RHR_15.07_eng.pdf. Accessed on 28 September 2025.
Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS. Contraceptive Technology. 21st edition. New York: Ayer Company Publishers. 2018.
Kennedy KI, Visness CM. Contraceptive efficacy of lactational amenorrhoea. Lancet. 1992;339(8787):227-30. DOI: https://doi.org/10.1016/0140-6736(92)90018-X
Petitti DB, Piaggio G, Mehta S, Cravioto MC. Steroid hormone contraception and risk of breast cancer. Contraception. 2004;70(1):3-22.
Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Risk of endometrial cancer following estrogen-progestin replacement therapy. Int J Cancer. 1999;82(1):38-42.
Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril. 1997;68(3):393-401. DOI: https://doi.org/10.1016/S0015-0282(97)00193-3
National Family Health Survey (NFHS-5), 2019-21: India. International Institute for Population Sciences (IIPS) and ICF. Mumbai: IIPS. 2021. Available at: https://dhsprogram.com/pubs/pdf/FR375/FR375.pdf. Accessed on 28 September 2025.
Rutstein SO. Effects of preceding birth intervals on neonatal, infant and under-five years mortality and nutritional status in developing countries: evidence from the demographic and health surveys. Int J Gynaecol Obstet. 2005;89:S7-24. DOI: https://doi.org/10.1016/j.ijgo.2004.11.012
Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA. 2006;295(15):1809-23. DOI: https://doi.org/10.1001/jama.295.15.1809
Ravindran TKS. Female autonomy in decision-making in rural India: impact of reproductive health programme. Reprod Health Matters. 2012;20(39):62-70.
Santhya KG. Changing family planning scenario in India: an overview of recent evidence. Indian J Med Res. 2014;140:S4-9.
Stephenson R, Baschieri A, Clements S, Hennink M, Madise N. Contextual influences on modern contraceptive use in sub-Saharan Africa. Am J Public Health. 2007;97(7):1233-40. DOI: https://doi.org/10.2105/AJPH.2005.071522
Khan ME, Bhatnagar I, Hazra A. Patterns and determinants of contraceptive use and unmet need in Uttar Pradesh. J Fam Welfare. 2008;54(1):1-19.
Roy TK, Singh BP, Roy A. Contraceptive use in India: trends and differentials. Demography India. 2003;32(2):281-98.
Halpern V, Lopez LM, Grimes DA, Stockton LL, Gallo MF. Strategies to improve adherence and acceptability of hormonal contraceptives. Cochrane Database Syst Rev. 2013;2013(10):CD004317. DOI: https://doi.org/10.1002/14651858.CD004317.pub4
Jain AK, Winfrey W. Contribution of contraceptive discontinuation to unintended births in 36 developing countries. Stud Fam Plann. 2017;48(3):269-78. DOI: https://doi.org/10.1111/sifp.12023
Ali MM, Cleland J. Contraceptive discontinuation, switching, abandonment and their reproductive consequences: An analysis of 1,539,071 episodes of reversible method use contributed from 61 countries that participated in DHS: Population base-analysis. PLOS Glob Public Health. 2025;5(10):e0005174. DOI: https://doi.org/10.1371/journal.pgph.0005174
Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis. 2013;13(9):797-808. DOI: https://doi.org/10.1016/S1473-3099(13)70155-5
Glasier A, Gulmezoglu AM, Schmid GP, Moreno CG, Van Look PF. Sexual and reproductive health: a matter of life and death. Lancet. 2006;368(9547):1595-607. DOI: https://doi.org/10.1016/S0140-6736(06)69478-6
Downloads
Published
How to Cite
Issue
Section
